Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...
Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...
The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that ...
Novavax, Inc. reported 3Q25 EPS loss & declining revenue, but beat revenue expectations & reaffirmed its FY25 guidance. Read ...
The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official [claimed the shots]( ...
Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM ESTCompany ParticipantsRuxandra Draghia-Akli - Executive VP ...
Novavax, Inc. (NASDAQ: NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced ...
Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...
Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...
On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory panel ...
Vinay Prasad, a top FDA official, blamed COVID shots for playing a role in the deaths of 10 children in a memo he sent to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback